Computational designing of multiepitope based vaccine (MEBV) candidate against human metapneumovirus (HMPV) using immunoinformatics approach
- 1School of Medical Science, Shandong Xiehe University
- 2School of Basic Medical Sciences, Institute of Genetics, Lanzhou University
- 3University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore
Abstract
Human metapneumovirus (HMPV) is a paramyxoviridae family respiratory pathogen, which is closely related to respiratory syncytial virus. It produces the symptoms of the flu and it may result in the serious damage of the airways and even though it is a worldwide problem, there is no vaccine available as yet. Three antigenic proteins namely surface glycoprotein, nucleoprotein and phosphoprotein were screened from all the receptors and showed no similarity to host genome. The three viral proteins were then screened for identifying the cytotoxic and helper T cell lymphocytes as well as linear and conformational B-cell lymphocytes. The vaccine had 13 MHC-I epitopes, one MHC-II epitope, and four linear B-cell epitopes, which were combined with linkers and beta-defensin as adjuvant into a 296-amino-acid MEBV with antigenicity score of 0.6644. Molecular docking and MD simulations showed that there is a high degree of interaction with human TLR3 with binding energy of − 14.6 and immune activation. Moreover, the disulfide engineering enhanced construct stability. Cloning and codon optimization was used to verify efficient expression in the target host. Taken together, these findings suggest that the proposed MEBV has potential as an immunogen of HMPV.
Related
- Integrative Machine Learning and Immunoinformatics-Guided Design and In Silico Validation of a Multiepitope DNA Vaccine Against Avian Metapneumovirus.
- In Silico Design and Immunogenicity Evaluation of a Multiepitope Vaccine Candidate Against Leishmania tropica in BALB/c Mice.
- Protocol for Designing and Interpreting Minigene Assays to Validate Candidate Splice-Altering Variants Using Long-read Sequencing.
- X-ray structure of the human Nijmegen breakage syndrome forkhead-associated/BRCA1 C-terminal domain and computational docking of candidate radiosensitizers
- Computational identification of candidate biomarkers and compounds associated with skeletal muscle insulin sensitivity improvement mediated by physical activity: an integrative multi-omics and computational chemistry study.
BibTeX
@article{naeem2026computational,
title = {{Computational designing of multiepitope based vaccine (MEBV) candidate against human metapneumovirus (HMPV) using immunoinformatics approach}},
author = {Sajid Naeem and Amna Rasheed and Aqsa Khan and Anas Azhar and Sajjad Ullah and Seerat Fatima},
journal = {Scientific Reports},
year = {2026},
month = sep,
doi = {10.1038/s41598-026-67755-9},
url = {https://doi.org/10.1038/s41598-026-67755-9},
note = {CC BY},
}
RIS
TY - JOUR
TI - Computational designing of multiepitope based vaccine (MEBV) candidate against human metapneumovirus (HMPV) using immunoinformatics approach
AU - Sajid Naeem
AU - Amna Rasheed
AU - Aqsa Khan
AU - Anas Azhar
AU - Sajjad Ullah
AU - Seerat Fatima
PY - 2026
DA - 2026/09/01
JO - Scientific Reports
DO - 10.1038/s41598-026-67755-9
UR - https://doi.org/10.1038/s41598-026-67755-9
AB - Human metapneumovirus (HMPV) is a paramyxoviridae family respiratory pathogen, which is closely related to respiratory syncytial virus. It produces the symptoms of the flu and it may result in the serious damage of the airways and even though it is a worldwide problem, there is no vaccine available as yet. Three antigenic proteins namely surface glycoprotein, nucleoprotein and phosphoprotein were screened from all the receptors and showed no similarity to host genome. The three viral proteins were then screened for identifying the cytotoxic and helper T cell lymphocytes as well as linear and conformational B-cell lymphocytes. The vaccine had 13 MHC-I epitopes, one MHC-II epitope, and four linear B-cell epitopes, which were combined with linkers and beta-defensin as adjuvant into a 296-amino-acid MEBV with antigenicity score of 0.6644. Molecular docking and MD simulations showed that there is a high degree of interaction with human TLR3 with binding energy of − 14.6 and immune activation. Moreover, the disulfide engineering enhanced construct stability. Cloning and codon optimization was used to verify efficient expression in the target host. Taken together, these findings suggest that the proposed MEBV has potential as an immunogen of HMPV.
SN - 2045-2322
ER -